What are the risks of haploidentical stem cell therapy?
Patient's Query
Hello Doctor,
My wife is 36 years old and urgently requires stem cell therapy for acute lymphoblastic leukemia (ALL), which has relapsed following chimeric antigen receptor T-cell (CAR-T) therapy. Her oncologist has indicated that a haploidentical stem cell transplant is the only remaining potentially curative option. However, we have serious concerns regarding the risks versus benefits.
Her disease has been incredibly aggressive. She was diagnosed 14 months ago and achieved remission with induction chemotherapy. Unfortunately, she relapsed seven months later with 64% blasts in the bone marrow. She subsequently failed immunotherapy with Blinatumomab (a bispecific T-cell engager antibody) and then received CAR-T therapy (a form of immunotherapy), which initially worked. However, she relapsed again just three months later.
Her current bone marrow shows 82% blasts, with complex cytogenetics, including the Philadelphia chromosome (Ph+), making her leukemia particularly hard to treat. She is physically extremely weak, her hemoglobin rarely rises above 8 g/dL despite regular transfusions, her platelets require support every 3–4 days, and her neutrophil count remains consistently below 500/mm³. She has also lost 37 pounds throughout her treatment.
The transplant center has recommended a haploidentical stem cell transplant using her brother (a half-matched donor), along with post-transplant cyclophosphamide (an immunosuppressive alkylating agent) to reduce the risks of rejection and graft-versus-host disease (GVHD). However, they also warned us that due to her active disease state and severely weakened condition, the risk of treatment-related mortality is very high.
They have also mentioned a clinical trial that combines stem cell transplantation with an experimental maintenance therapy, which could potentially improve outcomes. However, this trial is located several states away, making logistics and travel very challenging.
She is desperate to try anything that offers hope, but she is also terrified of enduring another round of grueling treatment that might only offer a small chance of success while significantly diminishing her quality of life.
My questions are:
What is the realistic success rate of stem cell transplantation in multiply-relapsed, Philadelphia chromosome-positive ALL?
How much additional survival time might stem cell therapy offer, even if it is not curative?
How do we balance quality versus quantity of life when faced with such difficult decisions?
Kindly help.
Hello,
Welcome to icliniq.com.
I have read your query and can understand your concern.
A) Her current condition:
Acute lymphoblastic leukemia (ALL) is – very aggressive subtype.
Multiple relapses despite undergoing the following treatments:
1. Chemotherapy.
2. Blinatumomab (Immunotherapy; bispecific T-cell engager antibody).
3. Chimeric antigen receptor T-cell (CAR-T) therapy (immunotherapy).
3. Philadelphia chromosome-positive (Ph+) with complex genetic abnormalities, making the disease particularly difficult to treat.
4. Physically very weak, with the following complications:
Chronically low blood counts.
Requires frequent blood and platelet transfusions.
Has lost a significant amount of body weight.
B) Why are they suggesting a haploidentical stem cell transplant now?
It is currently the only remaining potentially curative option, involving:
A haploidentical (half-matched) stem cell donor, which in her case would be her brother.
Post-transplant cyclophosphamide (an immunosuppressive alkylating agent) to reduce the risk of transplant rejection and graft-versus-host disease (GVHD).
However, due to her active disease and severely weakened physical condition, the risk of dying from the procedure itself (treatment-related mortality) is significantly high.
C) What are the chances of success?
In patients like your wife, who have relapsed/refractory Philadelphia chromosome-positive ALL, the estimated outcomes are as follows:
Long-term cure (3 or more years): approximately 10% to 20%, only if the transplant is successful and major complications are avoided.
One-year survival: around 30% to 40% on average, though lower in frail and heavily pretreated patients.
Transplant-related mortality (TRM): estimated at 30% to 50% in very ill patients who have undergone multiple prior treatments.
I hope this helps.
Thank you.
Same symptoms don't mean you have the same problem. Consult a doctor now!
Disclaimer: No content published on this website is intended to be a substitute for professional medical diagnosis, advice or treatment by a trained physician. Seek advice from your physician or other qualified healthcare providers with questions you may have regarding your symptoms and medical condition for a complete medical diagnosis. Do not delay or disregard seeking professional medical advice because of something you have read on this website. Read our Editorial Process to know how we create content for health articles and queries.